BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cytox Blood Test Shows Statistically Significant Association With Alzheimer's Disease (AD), May Predict Conversion of Mild Cognitive Impairment to AD


7/16/2009 8:23:20 AM

The blood test measures the integrity of the cell cycle G1/S restriction point in peripheral blood lymphocytes. Dr. Nagy, the inventor of the test and scientific co-founder of Cytox Ltd, was the principal investigator of the study, which was conducted in collaboration with the Oxford Project to Investigate Memory and Aging (OPTIMA). According to Dr. Nagy, "The results of this study support the cell cycle hypothesis of Alzheimer's disease - specifically, that G1/S cell cycle regulatory failure leads to the downstream development of the characteristic pathologies of the disease, the amyloid plaques and tau tangles. Most importantly, the findings validate the use of our lymphocyte test as a biomarker of Alzheimer's disease and suggest that the test is predictive of cognitive deficit developing in MCI patients."

About Cytox Limited

Cytox is a UK company developing products and services for neurodegenerative disorders. The company provides biomarker services to pharmaceutical industry clients conducting clinical trials with drugs for the treatment of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Cytox's blood tests enable the prediction of which patients with MCI will develop AD. The biomarkers are based on the cell cycle hypothesis of AD and were invented by Dr. Zsuzsanna Nagy at the University of Oxford and the University of Birmingham. For more information about Cytox, please visit the web site at http://www.cytoxgroup.com/.

Contact: Richard Hadden, CEO: tel: +44 20 7250 4210; email: richard.hadden@cytoxgroup.com

SOURCE Cytox Limited

CONTACT: Richard Hadden, CEO of Cytox Limited, +44 20 7250 4210,
richard.hadden@cytoxgroup.com

Web site: http://www.cytoxgroup.com/



Read at BioSpace.com

Cytox
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->